article thumbnail

Framework Benchmarks Round 22

TechEmpower

synopse I have written a blog post about TFB and object pascal - yes, we added our object pascal framework in round 22! Context and use case determines how you optimize your code. btw: xitca-web (bench code not including dependencies) does not do 2,3,5 and still remains competitive in micro bench can be used as a reference.

Framework 409
article thumbnail

Take this test to predict your success:

Berkonomics

Is it the advantage of time – years of development ahead of any competitor? Do you have a world-class management team? Do anything you can to develop compelling products or early prototypes as proof of ability to reduce your technology risk. What can you prove as a barrier to entry for competitors? Are margins high enough?

Patents 156
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines

Xconomy

An Amgen migraine drug developed to head off pain before it starts has won FDA approval, the first for a new class of preventive drug candidates for the condition. The Amgen (NASDAQ: AMGN ) drug, erenumab (Aimovig), is a subcutaneous injection given once a month.

Class 78
article thumbnail

Lundbeck’s Alder Bio Bet Pays Off With FDA Approval of Migraine Drug

Xconomy

The drug, eptinezumab (Vyepti), is part of a new class of antibody therapies developed to prevent migraine attacks before they start. The first three drugs from this class that won FDA approval for migraine prevention are injectable therapies.

Class 105
article thumbnail

Five Years After Y Combinator First Admits Biotechs, They’re Dug In

Xconomy

Five years ago, the big tech incubator Y Combinator started to welcome life sciences companies into its sizable startup classes, which had previously nurtured entrepreneurs in information technology almost exclusively. That opening to biotech startups in 2014 was controversial at the time.

Incubator 108
article thumbnail

At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments

Xconomy

The first new class of migraine drugs in decades won FDA approval last year. The new class of migraine drugs are called calcitonin gene-related peptide (CGRP) inhibitors, named for a protein associated with the development of migraine pain. By blocking CGRP, the drugs are meant to abort migraine.

Class 89
article thumbnail

Life Sciences IPOs Target Collective Raise of More Than $600M This Week

Xconomy

By month’s end, five more are anticipated to join the class of 2020 initial public offerings—and four of those are in life sciences, according to IPO research firm Renaissance Capital. Cancer drug developer Black Diamond filed IPO paperwork with regulators on Jan. 7 detailing its plans to use to the cash to finance Phase 1/2.